Skip to content
Austin Top 50
Author:
Classover Holdings Inc.
Classover Enters into a Strategic Partnership with 1Legion to Deploy up to $50 Million GPU Infrastructure
May 26, 2026
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 22, 2026
Classover Enters into $100 Million Equity Purchase Facility Agreement and Announces Expansion into AI Compute Infrastructure and Cloud Services Platforms
May 22, 2026
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 16, 2026
Classover Reports First Quarter 2026 Results and Accelerates Transition Toward AI-Native Intelligent Robotics Ecosystems and Next-Generation Education Platforms
May 15, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 13, 2026
Classover Launches Embodied AI Robotics Education Platform Featuring Proprietary Curriculum Built on Advanced Humanoid Robotics Systems
May 11, 2026
Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 5, 2026
Classover Announces Strategic Collaboration With Vensin Computer Technology To Advance AI Robotics Education and Infrastructure
May 4, 2026
←
Previous Page
1
2
3
4
5
Next Page
→